<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357445</url>
  </required_header>
  <id_info>
    <org_study_id>BMETEU.CR.EU49</org_study_id>
    <nct_id>NCT03357445</nct_id>
  </id_info>
  <brief_title>AVANTAGE® RELOAD Double Mobility Acetabular Cup -Clinical Study</brief_title>
  <official_title>Prospective, Multi Centre Evaluation of AVANTAGE® RELOAD Double Mobility Acetabular Cup - Clinical and Radiographic Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Post Marketing Clinical Follow Up study (PMCF) on the AVANTAGE RELOAD dual mobility
      system cup.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to document the patients' survivorship at 10 years and evaluate the
      performances at 3 months, 1, 2, 3, 5, 7 and 10 years post-surgery of the AVANTAGE RELOAD cup.
      Secondary objective is to evaluate the polyethylene wear between E1 and ARCOM.

      500 patients was the enrollment goal with 2 subgroups.

        -  Subgroup 1: prospective and non-controlled to satisfy ODEP (Orthopedic Device Evaluation
           Panel) requirements;

        -  Subgroup 2: randomized and controlled to compare the polyethylene wear between the Arcom
           and the E1 liners.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 14, 2011</start_date>
  <completion_date type="Anticipated">April 27, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 27, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The two subgroups will have the medical device with the following objectives:
Subgroup 1 Prospective non Controlled to Document long term performance of AVANTAGE® RELOAD.
Subgroup 2 Randomized Controlled Trial to Evaluate wear rate of E1 liner in comparison to ArCom® liner.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Survivorship</measure>
    <time_frame>10 years post-surgery</time_frame>
    <description>Implant survivorship</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Harris hip scores</measure>
    <time_frame>10 years post-surgery</time_frame>
    <description>To measure clinical efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>10 years post-surgery</time_frame>
    <description>To measure clinical efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Evaluation</measure>
    <time_frame>10 years post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>10 years post-surgery</time_frame>
    <description>Eventual complications occurred including dislocations and revisions/removals</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Primary Osteoarthritis</condition>
  <condition>Post-Traumatic Arthritis</condition>
  <condition>Inflammatory Joint Disease</condition>
  <condition>Femoral Neck Fracture</condition>
  <condition>Femoral Head Necrosis</condition>
  <condition>Sequelae From Previous Hip Surgery</condition>
  <condition>Osteotomies</condition>
  <condition>Congenital Hip Dysplasia</condition>
  <arm_group>
    <arm_group_label>Subgroup 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Prospective non Controlled to Document long term performance of AVANTAGE® RELOAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subgroup 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Randomized Controlled Trial to Evaluate wear rate of E1 liner in comparison to ArCom® liner</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Avantage Reload cup</intervention_name>
    <description>Patients receiving the Avantage Reload acetabular cup in total hip arthroplasty</description>
    <arm_group_label>Subgroup 1</arm_group_label>
    <arm_group_label>Subgroup 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Selection of subjects for this evaluation should be in accordance with the indications
             of the AVANTAGE® RELOAD with E1™ or ArCom™ liner specifically

               -  Primary osteoarthritis

               -  Post-Traumatic arthritis

               -  Inflammatory joint disease (e.g. Rheumatoid arthritis)

               -  Femoral neck fracture

               -  Femoral head necrosis

               -  Sequelae from previous hip surgery, osteotomies, etc.

               -  Congenital hip dysplasia

        Additional inclusion criteria include:

          -  Male or female

          -  18 years of age or older

          -  Subjects willing to return for follow-up evaluations

          -  Subjects who read, understand study information and give written consent (specific
             local regulatory requirements)

        Exclusion Criteria:

          -  Exclusion criteria should be in accordance with Contraindications for the AVANTAGE®

        RELOAD:

        Absolute contraindications include:

          -  Infection

          -  Sepsis

          -  Severe muscular, neurological or vascular deficiencies of the extremity involved

          -  Bone destruction or poor bone quality

        Additional contraindications include:

          -  Subjects unable to co-operate with and complete the study

          -  Dementia and inability to understand and follow instructions

          -  Neurological conditions affecting movement

          -  Patient over 18 under law supervision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paola Vivoda</last_name>
    <role>Study Director</role>
    <affiliation>Zimmer Biomet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Cote de Nacre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Renée Sabran</name>
      <address>
        <city>Giens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Nicolas</name>
      <address>
        <city>Sarrebourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Novo Mesto</name>
      <address>
        <city>Novo Mesto</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Bellvitg</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Slovenia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2017</study_first_submitted>
  <study_first_submitted_qc>November 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2017</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total hip Arthroplasty</keyword>
  <keyword>Hip implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Femoral Neck Fractures</mesh_term>
    <mesh_term>Hip Dislocation</mesh_term>
    <mesh_term>Hip Dislocation, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

